文献速递骨软组织肉瘤与黑色素瘤

转移性葡萄膜黑色素瘤及转移性GNA11/GNAQ突变黑色素细胞肿瘤患者中替本他福普与免疫检查点抑制剂的治疗顺序

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.
PubMed 文献 · Eur J Cancer · 2024-11-30

回顾性纳入131例HLA-A*02:01阳性转移性葡萄膜黑色素瘤或转移性GNA11/GNAQ突变黑色素细胞肿瘤患者,比较替本他福普后免疫检查点抑制剂(ICI)序贯(第1组,51例)与反向序贯(第2组,80例)的疗效与安全性。第2组中位总生存期33.6个月(95%CI 28.9-43)优于第1组22.4个月(95%CI 19-24.8),p=0.004。作者认为两种顺序临床可行,ICI后替本他福普序贯观察到临床获益,但受回顾性研究限制,需前瞻性临床试验进一步研究。

要点

  • 第1组(替本他福普后ICI)中位OS为22.4个月(95%CI 19-24.8),第2组(ICI后替本他福普)为33.6个月(95%CI 28.9-43),p=0.004。
  • 第1组总中位PFS为12个月(95%CI 10.7-18.8),第2组为20.3个月(95%CI 17.2-27.3),p=0.04。
  • 细胞因子释放综合征在第2组更常见(15% vs 27%),作者认为两种治疗顺序临床均可行。

核心结论

  • 两种治疗顺序临床均可行;ICI后替本他福普的序贯组合观察到临床获益。
  • 该观察受回顾性研究性质限制,需在前瞻性临床试验中进一步研究。

研究设计与样本

  • 回顾性识别接受替本他福普后ICI序贯(第1组)或反向序贯(第2组)的任何治疗线患者。
  • 纳入HLA-A*02:01阳性转移性葡萄膜黑色素瘤或转移性GNA11/GNAQ突变黑色素细胞肿瘤患者,共131例,第1组51例,第2组80例。
  • 主要目标为2年总生存率。

主要发现

  • 基线乳酸脱氢酶正常者第1组为30%,第2组为40%,p=0.05。
  • 多叶肝病者第1组为94%,第2组为77%,p=0.02。
  • 中位OS第1组为22.4个月(95%CI 19-24.8),第2组为33.6个月(95%CI 28.9-43),p=0.004。
  • 总中位PFS第1组为12个月(95%CI 10.7-18.8),第2组为20.3个月(95%CI 17.2-27.3),p=0.04。
  • 细胞因子释放综合征频率第1组为15%,第2组为27%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究为回顾性性质。
  • 需在前瞻性临床试验中进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metastatic uveal melanoma (mUM) is rare. Immune checkpoint inhibitors (ICIs) have shown modest efficacy in mUM. Tebentafusp prolonged overall survival (OS) in a phase 3 study. We aimed to investigate the efficacy and safety of the sequence of tebentafusp and ICIs. METHODS: Patients with HLA-A * 02:01 positive mUM, or metastatic GNA11/GNAQ mutant melanocytic tumors treated with tebentafusp followed by ICIs (group 1) or the inverse sequence (group 2) at any treatment line were retrospectively identified. The primary objective was OS rate at 2 years. RESULTS: 131 patients were included; 51 in group 1 and 80 in group 2. 30 % in group 1 % and 40 % in group 2 had normal baseline lactate dehydrogenase (LDH, p = 0.05). 94 % in group 1 % and 77 % in group 2 had multilobular liver disease (p = 0.02). Median OS was 22.4 months (95 % CI 19-24.8) in group 1 and 33.6 months (95 % CI 28.9-43) in group 2 (p = 0.004). Total median PFS was 12 months (95 % CI 10.7-18.8) in group 1 and 20.3 months (95 % CI 17.2-27.3) in group 2 (p = 0.04). The frequency of cytokine release syndrome was higher in group 2 (15 % vs 27 %). Other clinical factors were associated with short total PFS in the multivariable analysis. CONCLUSIONS: Both treatment sequences are clinically feasible. A clinical benefit was noted in the sequential combination of ICIs followed by tebentafusp. This observation is limited by the retrospective nature of the study and merits further investigation in prospective clinical trials.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Dimitriou F, Orloff MM, Koch Hein EC, et al. Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors. Eur J Cancer. 2024. PMID: 39647344. doi:10.1016/j.ejca.2024.115161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。